RESEARCH TRIANGLE PARK — Asklepios BioPharmaceutical has a new chief business officer (CBO).

Don Haut, PhD, who previously served as CBO at Sherlock Biosciences and Histogenics, is taking on the role at the clinical-stage adeno-associated virus (AAV) gene therapy company based in RTP.

“Don has a wealth of strategy and business development experience in the biotechnology and medical technology fields. His expertise will prove extremely valuable as AskBio continues to advance platforms and partnerships to aid in the development of the next generation of gene therapies,” said Sheila Mikhail, AskBio CEO and co-founder, in a statement.

Don Haut, Source: LinkedIn

Haut brings more than two decades of healthcare experience to AskBio. Prior to Sherlock Biosciences and Histogenics, he was vice president for New Business and vice president for American Sales Operations at The Medicines Company.

In addition, he held leadership roles in strategy and business development at Smith & Nephew’s Advanced Surgical Devices and Endoscopy divisions, was Director of Strategy and Business Development at 3M Company, and was a principal at JSB Partners. He began his career with roles at Monsanto and McKinsey & Company. Dr. Haut currently serves on the board of directors of Xiros Ltd. He earned an MBA from Washington University’s Olin School of Business and a PhD in molecular biology from the University of Missouri-Columbia.

“AskBio has a successful history of forming strategic collaborations with many of the world’s top organizations to expand what’s possible in gene therapy,” said Haut. “We plan to advance that path and are motivated by all the terrific programs we’re seeing.”

AskFirst: AskBio’s new gene therapy program for clinical trial patients